CRM surged 22.6% on its earnings beat. Analysts rushed to raise targets. Yet options traders are the most defensively positioned in 52 weeks — and that tension is the story.
Ten firms raised price targets on August 27 alone. Jefferies went to $300. TD Cowen lifted to $280. Barclays moved to $276. JP Morgan raised to $265, as did Mizuho. BMO Capital went to $260. Even Bernstein — maintaining an Underperform — lifted its target to $195 from $173.
The mean analyst target now sits at $262.54. With CRM trading at $252.05, that implies modest upside from current levels. Jefferies' $300 target is the outlier bull case. Bernstein's $195 is the floor.
No firm upgraded its rating. Every action was a target raise on a held rating. The Street is more constructive — but not yet convinced enough to change conviction.
Here's the odd part. As the stock climbed, options traders bought more puts relative to calls, not fewer.
The put/call ratio hit 0.9368 on August 27. That's a 52-week high. It sits 2.56 standard deviations above its 20-day mean of 0.847. Before earnings, it had already touched 0.91 — itself flagged as a record at the time. Since the print, it's pushed even higher.
Two interpretations exist. First, holders are locking in gains with protective puts after a violent move. Second, some traders remain skeptical the rally holds. Either way, the options market is sending a notably cautious signal into what should be a clean post-earnings period.
Short interest fell to 2.91% of free float — down 15% over the past week and down more than 34% over the past month. Bears have largely exited. This is consistent with the picture in previous notes: shorts began unwinding well before earnings, and the post-print surge accelerated that process.
The borrow market remains extremely loose. Availability sits at 5,133% — for every share currently shorted, more than 51 shares are available to lend. There is no squeeze pressure in the data.
Cost to borrow did rise 57% over the week to 0.43%. That sounds dramatic. In absolute terms it is not — 0.43% is a very low rate. But the direction is worth noting: as short sellers cover and fewer borrowed shares remain outstanding, the cost per borrowed share can drift higher even as aggregate borrowing falls. It's a mechanical effect more than a signal of new short demand.
The PCR at a 52-week high is the live tension. If it fades toward the 20-day mean in coming sessions, it reads as post-earnings hedging that has run its course. If it stays elevated or pushes higher as the stock consolidates, the defensive options positioning may be telling a more substantive story about how holders view CRM at $252.
See the live data behind this article on ORTEX.
Open CRM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
